J&J Is Said to Be in Talks to Acquire Intra-Cellular (2)

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said.

A deal could be reached as soon as this week, according to the people, who asked not to be identified discussing confidential information. While discussions are ongoing, they may not lead to an agreement and other suitors could also emerge, they said.

Shares of Intra-Cellular rose as much as 21% in early trading before the market opened in New York. The stock has risen about 40% over the last 12 months, ...